Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EPHA2 | P29317 | 4/20 | 0.45 |
| ▸ | YAP1 | P46937 | 3/20 | 0.41 |
| ▸ | MAPT | P10636 | 2/20 | 0.41 |
| ▸ | HPGD | P15428 | 2/20 | 0.41 |
| ▸ | MEN1 | O00255 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.41 |
| ▸ | LMNA | P02545 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.41 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.41 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.40 |
| ▸ | ERBB2 | P04626 | 1/20 | 0.40 |
| ▸ | EPHB4 | P54760 | 1/20 | 0.40 |
| ▸ | TLR9 | Q9NR96 | 3/20 | 0.39 |
| ▸ | TLR7 | Q9NYK1 | 2/20 | 0.39 |
| ▸ | PARP1 | P09874 | 1/20 | 0.39 |
| ▸ | JAK2 | O60674 | 1/20 | 0.39 |
| ▸ | JAK1 | P23458 | 1/20 | 0.39 |
| ▸ | GPR119 | Q8TDV5 | 1/20 | 0.39 |
| ▸ | S1PR4 | O95977 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1552680 | 0.87 | EPHA2 (0.50) | EPHA2ALDH1A1KMT2AERBB2EPHB4 | |
| SCHEMBL1552682 | 0.87 | EPHA2 (0.50) | EPHA2ALDH1A1KMT2AERBB2EPHB4 | |
| SCHEMBL1552040 | 0.85 | YAP1 (0.51) | YAP1LMNAJAK2JAK1GPR119 | |
| SCHEMBL27715096 | 0.85 | YAP1 (0.51) | YAP1LMNAJAK2JAK1GPR119 | |
| SCHEMBL27715065 | 0.84 | YAP1 (0.50) | YAP1LMNAJAK2JAK1GPR119 | |
| SCHEMBL4476703 | 0.83 | JAK2 (0.49) | EPHA2LMNASMN1; SMN2JAK2JAK1 | |
| SCHEMBL1553166 | 0.83 | EPHA2 (0.44) | EPHA2MAPTLMNASMN1; SMN2ERBB2 | |
| SCHEMBL1553137 | 0.83 | EPHA2 (0.44) | EPHA2MAPTLMNASMN1; SMN2ERBB2 | |
| SCHEMBL31076404 | 0.82 | EPHA2 (0.45) | EPHA2MAPTMEN1KMT2ASMN1; SMN2 | |
| SCHEMBL1552614 | 0.82 | EPHA2 (0.51) | EPHA2MEN1KMT2ASMN1; SMN2ERBB2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1844026-B1 | MORPHOLINES AS 5HT2C AGONISTS | HOFFMANN LA ROCHE (CH) | 2011-04-27 | — | — | EP | disclosed |
| CN-101107235-B | Morpholines as 5HT2C agonists | HOFFMANN LA ROCHE | 2011-03-16 | — | — | CN | disclosed |
| US-7323466-B2 | Morpholine derivatives as 5HT2C receptor agonists for the treatment of obesity | HOFFMAN-LA ROCHE INC. (US) | 2008-01-29 | — | — | US | disclosed |
| CN-101107235-A | Morpholines as 5HT2C agonists | HOFFMANN LA ROCHE (CH) | 2008-01-16 | — | — | CN | disclosed |
| US-20060178510-A1 | New morpholine derivatives as 5HT2C receptor agonists for the treatment of obesity | HOFFMANN-LA ROCHE INC. | 2006-08-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060178510-A1 | New morpholine derivatives as 5HT2C receptor agonists for the treatment of obesity | HTR2C, HTR1A, HTR1B | EPHA2 3530/4885YAP1 4012/4885MAPT 3287/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.